Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7320872 | 0.79 | L3MBTL3 (0.45) | L3MBTL1HRH3 | |
| SCHEMBL20160890 | 0.79 | L3MBTL3 (0.42) | L3MBTL1TRIM24TRIM33HRH3 | |
| SCHEMBL14919428 | 0.78 | — | — | |
| SCHEMBL10538464 | 0.77 | L3MBTL3 (0.44) | ALDH1A1L3MBTL1TRIM24TRIM33HRH3 | |
| SCHEMBL7314532 | 0.77 | L3MBTL3 (0.44) | ALDH1A1L3MBTL1TRIM24TRIM33HRH3 | |
| SCHEMBL1799606 | 0.74 | SMN1; SMN2 (0.46) | ALDH1A1L3MBTL1GRIN2BHRH3OPRL1 | |
| SCHEMBL29132584 | 0.74 | HPGD (0.44) | ALDH1A1L3MBTL1GRIN2BHRH3OPRM1 | |
| SCHEMBL864488 | 0.74 | L3MBTL3 (0.40) | ALDH1A1L3MBTL1OPRM1OPRL1 | |
| SCHEMBL1799353 | 0.74 | L3MBTL3 (0.39) | ALDH1A1LMNAL3MBTL1GRIN2BHRH3 | |
| SCHEMBL121604 | 0.74 | L3MBTL3 (0.34) | ALDH1A1L3MBTL1TRIM24TRIM33HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097375-B | Cyclohexyl-azetidine the antagonist of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-08-12 | — | — | CN | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-8518969-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-27 | — | — | US | disclosed |
| CN-103097375-A | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV | 2013-05-08 | — | — | CN | disclosed |
| EP-2582692-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159854-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTAICA N.V. (BE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312936-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ALDH1A1 530/4885LMNA 4185/4885L3MBTL1 2052/4885 |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ALDH1A1 530/4885LMNA 4185/4885L3MBTL1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.